This article is more than 5 years old. Information may no longer be current.

Rapid DNA test for CYP2C19 variants receives FDA clearance

Issue: October 25, 2013

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Spartan Bioscience announced that it has received FDA clearance for a rapid genetic testing device that identifies variants in the CYP2C19 gene.

The Spartan RX CYP2C19 System provides genetic results from a cheek swab in less than 60 minutes, according to information from a company press release.

The device is indicated for use to help physicians determine the best therapeutic strategy for drugs that are metabolized by the CYP450 2C19 genetic pathway, as some patients carry CYP2C19 gene variants that hamper response to those drugs, the company stated in the press release.

Drugs metabolized by the CYP450 2C19 genetic pathway include the antiplatelet therapy clopidogrel (Plavix, Sanofi Aventis), the beta-blocker propranolol, the antidepressant citalopram (Celexa, Forest), the proton pump inhibitor omeprazole and the anti-epileptic phenytoin.